Drug Trial Radar · NCT05686356
A Pan-TB Regimen Targeting Host and Microbe
Last checked: Nov 19, 2026Latest source record: May 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
352
Planned (sponsor's estimate)
Start
Jul 28, 2023
Primary completion
Jan 2026
Study completion Jan 2026
Sponsor
- Lead sponsor
- The Aurum Institute NPCAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ludwig-Maximilians - University of Munich; Stichting Katholieke Universiteit; Wits Health Consortium (Pty) Ltd; Instituto Nacional de Saúde, Mozambique; National Institute for Medical Research, Tanzania; University of Stellenbosch; Sequella, Inc.; Global Alliance for TB Drug Development
- First posted
- Jan 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This project will develop the first regimen meeting WHO criteria for a pan-TB indication, ie, not requiring knowledge of RIF susceptibility. The regimen will test sutezolid at 2 dose levels, with the approved anti-TB drugs bedaquiline and pretomanid, in a phase 2c trial. It will also test whether the addition of N-acetylcysteine (NAC), a re-purposed host-directed WHO essential medicine, can protect the lung and liver against oxidative damage, preserve lung function, and accelerate the eradication of MTB infection by replenishing glutathione (GSH).
Conditions
- Tuberculosis
Interventions
SutezolidDrug
Sutezolid will be given at a dose of 1200mg QD in arm 1 and at a dose of 1600mg QD in arms 2 and 3.
N-acetyl cysteineDrug
NAC will be given at a dose of 1800 mg BID in arm 3
PretomanidDrug
Pretomanid will be given at its approved dose
BedaquilineDrug
Bedaquiline will be given at its approved dose
RifafourCombination product
Fixed dose combination tablets for TB treatment will be given at approved doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of patients achieving durable (non-relapsing) cureTime frame: Assessed after 1 year of post-treatment follow-up
Locations
8 sites in 3 countries. Site status is shown where the registry gives one.
Instituto Nacional de Saúde
Maputo, Mozambique
Clinical HIV Research Unit
Durban, Durban, South Africa
Clinical HIV Research Unit
Johannesburg, Gauteng, South Africa
The Aurum Institute: Tembisa Clinical Research Centre
Tembisa, Gauteng, South Africa
The Aurum Institute, Gavin J Churchyard Legacy Centre (Klerksdorp Clinical Research Centre)
Klerksdorp, Klerksdorp, South Africa
The Aurum Institute, Rustenburg Clinical Research Centre
Rustenburg, North West Provice, South Africa
TASK Eden
George, Western Cape, South Africa
NIMR-Mbeya Medical Research Centre
Mbeya, Tanzania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.